載入...
COMBINATION THERAPY WITH GLP-1 RECEPTOR AGONIST AND SGLT2 INHIBITOR
The SGLT2 inhibitors (SGLTi) and glucagon-like-1 receptor agonists (GLP-1 RAs) effectively reduce HbA1c, but via very different mechanisms, making them an effective duet for combination therapy. Recently, drugs in both of these antidiabetic classes have been shown to reduce cardiovascular events, mo...
Na minha lista:
| 發表在: | Diabetes Obes Metab |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5643008/ https://ncbi.nlm.nih.gov/pubmed/28432726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12982 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|